To see the early effect of sorafenib on brain, heart and reproductive functions in patients with fibromatosis
Not Applicable
- Conditions
- Health Condition 1: D219- Benign neoplasm of connective andother soft tissue, unspecified
- Registration Number
- CTRI/2023/05/052509
- Lead Sponsor
- Desmoid Tumor Research Foundation (DTRF)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Patients more than 18 years with histologically proven diagnosis of fibromatosis
2. Started on sorafenib within previous 2-3 months of start of study
3. No previously diagnosed cardiovascular/ neurological/ menstrual problems
4. Has not received previous chemotherapy
5. Should be able to perform the cognitive tasks
Exclusion Criteria
Patients who canâ??t give informed consent
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To study the early effect of sorafenib therapy on the cardiovascular, cognitive and reproductive functions in the patients with desmoid tumor <br/ ><br>Timepoint: Baseline, 3 month, 6 month and 12 month
- Secondary Outcome Measures
Name Time Method To study the association of primary outcomes with the dose and duration of sorafenib therapyTimepoint: Baseline, 3 month, 6 month and 12 month